Plasma estrone sulfate concentrations and genetic variation at the CYP19A1 locus in postmenopausal women with early breast cancer treated with letrozole
Gianluigi Lunardi(Ospedale Sacro Cuore Don Calabria), Lucia Del Mastro(Ospedale Policlinico San Martino), Claudia Bighin(Azienda Ospedaliera S.Maria), Martina Serra(University of Genoa), Paolo Bruzzi(Alleanza Contro il Cancro), Giovanna Cavazzini(University of Padua), Mauro Porpiglia(Ospedale Sant'Anna), Ornella Garrone(Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), Paola Marroni(Ospedale Policlinico San Martino), Patrizia Piccioli(Ospedale Policlinico San Martino), Matteo Clavarezza(Ente Ospedaliero Ospedali Galliera), Giancarlo Bisagni, Sonia Lastraioli(Ospedale Policlinico San Martino), Riccardo Ponzone(Candiolo Cancer Institute), Rosario Notaro, Fabio Puglisi(University of Udine)
Cited by 23
Related Papers
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751